Trial reportAnnals of surgical oncology2026
The Role of Locoregional Treatment in Non-Progressive De Novo Metastatic Breast Cancer under Systemic Treatment: A Randomized Controlled Trial (LTMBC).
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLess than 10% of breast cancer patients have distant metastatic lesions (DnMBC) at the time of diagnosis. The overall survival (OS) of this group has been prolonged by advances in systemic therapies (ST) in recent decades. This study aimed to evaluate the role of locoregional treatment (LRT) in de novo metastatic breast cancer (DnMBC), which is non-progressive under ST.
methodsThe DnMBC patients who did not progress under ST were randomized to LRT and ST groups. The LRT group underwent a free-margin lumpectomy or mastectomy and axillary surgery with or without adjuvant radiotherapy. All the patients received maintenance ST thereafter and were visited every 3 months. The primary endpoint was OS.
resultsBetween 2018 and 2023, 250 patients were randomly assigned between the LRT (n = 158) and ST (n = 92) groups. The two groups were similar in terms of age and subtype. A 2-year OS of 81% and a 5-year OS of 43% were observed in the entire cohort. The estimated median time to death was 53 months (95% confidence interval [CI], 45-61 months) in the LRT group and 55 months (95% CI, 44-66 months) in the ST group. The log-rank test (p = 0.6) and adjusted Cox regression (hazard ratio [HR], 0.08; 95% CI, 0.9-1.3; p = 0.35) showed no OS differences between the LRT and ST groups. Patients with human epidermal growth factor receptor 2 (HER2+) (HR, 1.86; 95% CI, 1.21-2.87; p = 0.005) and lung metastasis (HR, 1.5, 95% CI, 1.04-2.26, p = 0.03) had an increased risk of death.
conclusionIn DnMBC, LRT is not associated with improved OS. Those with lung metastasis and HER2+ disease had a higher risk of death.
Indexed as
Identifiers
42472751What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.